CHANGES IN RETINAL BLOOD FLOW IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION BEFORE AND AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB

Taiji Nagaoka, Kenji Sogawa, Akitoshi Yoshida
2014 Retina  
word count: 232 words Nagaoka et al.--2 Abstract Purpose: To investigate the effect of intravitreal bevacizumab (IVB) injections for macular edema secondary to acute branch retinal vein occlusion (BRVO) on the retinal microcirculation. Design: Prospective, interventional case series. Methods: We measured central macular thickness using spectral-domain optical coherence tomography and retinal blood flow (RBF) in untreated eyes with macular edema secondary to acute BRVO in occluded (V1) and
more » ... uded (V1) and opposite venules in affected eyes (V2) and the equivalent venules in contralateral eyes (V3), using laser Doppler velocimetry during follow-up and after IVB injection. Results: In 33 eyes with acute BRVO of less than 2 months duration at the first visit, we observed changes in the retinal microcirculation for 1 month; the macular edema improved spontaneously and the RBF was unchanged in 15 of 33 eyes, and the RBF increased by 23.3% in 18 eyes with persistent macular edema. Twenty-four eyes received an IVB injection (1.25 mg/0.05 mL). The RBF did not change significantly during follow-up. In eight (33%) of 24 eyes with improved macular edema 3 months after treatment, the average RBF values before injection were significantly higher compared with eyes with recurrent edema. Conclusions: One IVB injection might have little effect on the retinal microcirculation in patients with macular edema secondary to acute BRVO at least 3 months after injection. However, the increased RBF in the occluded venules before injection might be associated with improved macular edema after the IVB injection. Nagaoka et al.--3 Key Words anti-VEGF therapy, branch retinal vein occlusion, macular edema, intravitreal injection, retinal blood flow. bevacizumab therapy for macular edema associated with branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2010;248:963-971. 4. Cheng KC, Wu WC, Chen KJ. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion. Eye (Lond) 2009;23:2023-2033. 5. Higashiyama T, Sawada O, Kakinoki M, et al. Prospective comparisons of intravitreal injections of triamcinolone acetonide and bevacizumab for macular oedema due to branch retinal vein occlusion. Acta Ophthalmol (Epub ahead of print). 6. Kim KS, Chang HR, Song S. Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion. Acta Ophthalmol 2008;86:925-927. RBF (µl/min) 10.6±5.2 9.7±5.8 9.6±5.6 9.8±4.0 9.9±4.7 0.71 Values are expressed as means ± standard deviation. *Significant (P<0.05) vs. recurrence group. RBF = retinal blood flow; IVB, intravitreal injection of bevacizumab.
doi:10.1097/iae.0000000000000172 pmid:24896136 fatcat:4jtsuetkh5d33aacdw2zlhg5uu